Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 497 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SHERI A, Smith IE, Hills M, Jones RL, et al
    Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4266.
    PubMed     Text format     Abstract available


  2. LIU Y, Li ZY, Wang JN, Li X, et al
    Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4259.
    PubMed     Text format     Abstract available


  3. LOHMANN AE, Liebman MF, Brien W, Parulekar WR, et al
    Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
    Breast Cancer Res Treat. 2017 Apr 26. doi: 10.1007/s10549-017-4265.
    PubMed     Text format     Abstract available


  4. LOHMANN AE, Ennis M, Taylor SK, Goodwin PJ, et al
    Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4263.
    PubMed     Text format     Abstract available


  5. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4247.
    PubMed     Text format     Abstract available


  6. YOUNG-AFAT DA, van Gils CH, van den Bongard HJGD, Verkooijen HM, et al
    The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results.
    Breast Cancer Res Treat. 2017 Apr 25. doi: 10.1007/s10549-017-4242.
    PubMed     Text format     Abstract available


  7. VON HAGENS C, Walter-Sack I, Goeckenjan M, Osburg J, et al
    Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
    Breast Cancer Res Treat. 2017 Apr 24. doi: 10.1007/s10549-017-4261.
    PubMed     Text format     Abstract available


  8. KAIDAR-PERSON O, Zagar TM, Oldan JD, Matney J, et al
    Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4248.
    PubMed     Text format     Abstract available


  9. VAN RAMSHORST MS, Loo CE, Groen EJ, Winter-Warnars GH, et al
    MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4254.
    PubMed     Text format     Abstract available


  10. ALLAIRE BT, Ekwueme DU, Poehler D, Thomas CC, et al
    Breast cancer treatment costs in younger, privately insured women.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4249.
    PubMed     Text format     Abstract available


  11. LIU B, Yi Z, Guan X, Zeng YX, et al
    The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis.
    Breast Cancer Res Treat. 2017 Apr 21. doi: 10.1007/s10549-017-4246.
    PubMed     Text format     Abstract available


  12. DUDENKOV TM, Ingle JN, Buzdar AU, Robson ME, et al
    SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
    Breast Cancer Res Treat. 2017 Apr 20. doi: 10.1007/s10549-017-4243.
    PubMed     Text format     Abstract available


  13. REYES ME, Fujii T, Branstetter D, Krishnamurthy S, et al
    Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4233.
    PubMed     Text format     Abstract available


  14. SOUCISE A, Vaughn C, Thompson CL, Millen AE, et al
    Sleep quality, duration, and breast cancer aggressiveness.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4245.
    PubMed     Text format     Abstract available


  15. ABDEL-RAHMAN O
    Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis.
    Breast Cancer Res Treat. 2017 Apr 17. doi: 10.1007/s10549-017-4244.
    PubMed     Text format     Abstract available


  16. HAN J, Choi YL, Kim H, Choi JY, et al
    MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 13. doi: 10.1007/s10549-017-4234.
    PubMed     Text format     Abstract available


  17. BALLINGER TJ, Kassem N, Shen F, Jiang G, et al
    Discerning the clinical relevance of biomarkers in early stage breast cancer.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4238.
    PubMed     Text format     Abstract available


  18. KUCHARCZYK MJ, Parpia S, Walker-Dilks C, Banfield L, et al
    Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
    Breast Cancer Res Treat. 2017 Apr 11. doi: 10.1007/s10549-017-4228.
    PubMed     Text format     Abstract available


  19. GRANT WB
    Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Apr 10. doi: 10.1007/s10549-017-4237.
    PubMed     Text format    


  20. ZHANG X, Brown JC, Paskett ED, Zemel BS, et al
    Changes in arm tissue composition with slowly progressive weight-lifting among women with breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Apr 8. doi: 10.1007/s10549-017-4221.
    PubMed     Text format     Abstract available


  21. MONFORT SM, Pan X, Patrick R, Ramaswamy B, et al
    Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4230.
    PubMed     Text format     Abstract available


  22. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Apr 3. doi: 10.1007/s10549-017-4219.
    PubMed     Text format    


  23. GOMEZ SL, Von Behren J, McKinley M, Clarke CA, et al
    Breast cancer in Asian Americans in California, 1988-2013: increasing incidence trends and recent data on breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4229.
    PubMed     Text format     Abstract available


  24. LEE GE, Mayer EL, Partridge A
    Prognosis of pregnancy-associated breast cancer.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4224.
    PubMed     Text format     Abstract available


  25. ANDREANO A, Rebora P, Valsecchi MG, Russo AG, et al
    Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach.
    Breast Cancer Res Treat. 2017 Apr 1. doi: 10.1007/s10549-017-4210.
    PubMed     Text format     Abstract available


    March 2017
  26. THOMAS LN, Chedrawe ER, Barnes PJ, Too CK, et al
    Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4223.
    PubMed     Text format     Abstract available


  27. MANDELBLATT JS, Cai L, Luta G, Kimmick G, et al
    Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).
    Breast Cancer Res Treat. 2017 Mar 31. doi: 10.1007/s10549-017-4222.
    PubMed     Text format     Abstract available


  28. HAMURCU Z, Kahraman N, Ashour A, Ozpolat B, et al
    FOXM1 transcriptionally regulates expression of integrin beta1 in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Mar 30. doi: 10.1007/s10549-017-4207.
    PubMed     Text format     Abstract available


  29. MOSHINA N, Sebuodegard S, Hofvind S
    Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program?
    Breast Cancer Res Treat. 2017 Mar 29. doi: 10.1007/s10549-017-4214.
    PubMed     Text format     Abstract available


  30. WOLLSCHLAGER D, Merzenich H, Schwentner L, Janni W, et al
    Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study).
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4215.
    PubMed     Text format     Abstract available


  31. CICCARESE M, Fabi A, Moscetti L, Cazzaniga ME, et al
    Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
    Breast Cancer Res Treat. 2017 Mar 28. doi: 10.1007/s10549-017-4213.
    PubMed     Text format     Abstract available


  32. LIM Y, Ko ES, Han BK, Ko EY, et al
    Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4217.
    PubMed     Text format     Abstract available


  33. HOLCAKOVA J, Nekulova M, Orzol P, Nenutil R, et al
    DeltaNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 27. doi: 10.1007/s10549-017-4216.
    PubMed     Text format     Abstract available


  34. KRAMMER J, Pinker-Domenig K, Robson ME, Gonen M, et al
    Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Mar 25. doi: 10.1007/s10549-017-4198.
    PubMed     Text format     Abstract available


  35. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2017 Mar 24. doi: 10.1007/s10549-017-4202.
    PubMed     Text format     Abstract available


  36. KAWAGUCHI H, Masuda N, Nakayama T, Aogi K, et al
    Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4212.
    PubMed     Text format     Abstract available


  37. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
    A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 23. doi: 10.1007/s10549-017-4211.
    PubMed     Text format     Abstract available


  38. STREKALOVA E, Malin D, Rajanala H, Cryns VL, et al
    Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4201.
    PubMed     Text format     Abstract available


  39. BASELGA J, Morales SM, Awada A, Blum JL, et al
    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4199.
    PubMed     Text format     Abstract available


  40. KIM GM, Kim S, Park HS, Kim JY, et al
    Chemotherapy-induced irreversible alopecia in early breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4204.
    PubMed     Text format     Abstract available


  41. JENDRIAN S, Steffens K, Schmalfeldt B, Laakmann E, et al
    Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4208.
    PubMed     Text format     Abstract available


  42. TRYFONIDIS K, Marreaud S, Khaled H, De Valk B, et al
    Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4203.
    PubMed     Text format     Abstract available


  43. MATTER-WALSTRA K, Schwenkglenks M, Dedes KJ
    Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
    Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209.
    PubMed     Text format    


  44. MUTI P, Secreto G, Krogh V
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2017 Mar 18. doi: 10.1007/s10549-017-4194.
    PubMed     Text format    


  45. FURLANETTO J, Jackisch C, Untch M, Schneeweiss A, et al
    Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4200.
    PubMed     Text format     Abstract available


  46. BOURKE M, Soden D, Clover AJ
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: a useful contributor to cutaneous disease control.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4187.
    PubMed     Text format    


  47. LIM YJ, Lee SW, Choi N, Kwon J, et al
    Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
    Breast Cancer Res Treat. 2017 Mar 17. doi: 10.1007/s10549-017-4206.
    PubMed     Text format     Abstract available


  48. ZHANG S, Gao X, Fu W, Li S, et al
    Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 16. doi: 10.1007/s10549-017-4189.
    PubMed     Text format     Abstract available


  49. TSENG LM, Chiu JH, Liu CY, Tsai YF, et al
    A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Breast Cancer Res Treat. 2017 Mar 15. doi: 10.1007/s10549-017-4195.
    PubMed     Text format     Abstract available


  50. GERSHUNI V, Li YR, Williams AD, So A, et al
    Breast cancer subtype distribution is different in normal weight, overweight, and obese women.
    Breast Cancer Res Treat. 2017 Mar 14. doi: 10.1007/s10549-017-4192.
    PubMed     Text format     Abstract available


  51. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Mar 13. doi: 10.1007/s10549-017-4191.
    PubMed     Text format     Abstract available


  52. KIMMICK GG, Major B, Clapp J, Sloan J, et al
    Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4188.
    PubMed     Text format     Abstract available


  53. YANAGAWA T, Kagara N, Miyake T, Tanei T, et al
    Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4190.
    PubMed     Text format     Abstract available


  54. KJARTANSDOTTIR OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, et al
    Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
    Breast Cancer Res Treat. 2017 Mar 9. doi: 10.1007/s10549-017-4171.
    PubMed     Text format     Abstract available


  55. RUGO HS, Melin SA, Voigt J
    Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4185.
    PubMed     Text format     Abstract available


  56. CAMPANA LG, Galuppo S, Valpione S
    Treatment of cutaneous metastases of breast cancer with electrochemotherapy: what is the magnitude of clinical benefit?
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4186.
    PubMed     Text format    


  57. CONWAY K, Edmiston SN, Parrish E, Bryant C, et al
    Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.
    Breast Cancer Res Treat. 2017 Mar 8. doi: 10.1007/s10549-017-4178.
    PubMed     Text format     Abstract available


  58. BINGHAM C, Fernandez SV, Fittipaldi P, Dempsey PW, et al
    Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4176.
    PubMed     Text format     Abstract available


  59. CORNELISSEN AJ, Kool M, Lopez Penha TR, Keuter XH, et al
    Lymphatico-venous anastomosis as treatment for breast cancer-related lymphedema: a prospective study on quality of life.
    Breast Cancer Res Treat. 2017 Mar 7. doi: 10.1007/s10549-017-4180.
    PubMed     Text format     Abstract available


  60. LEOPOLD RB, Thomas AW, Concannon KF, Correll AD, et al
    Breast cancer screening in patients with cancers other than breast.
    Breast Cancer Res Treat. 2017 Mar 6. doi: 10.1007/s10549-017-4179.
    PubMed     Text format     Abstract available


  61. ENGSTROM MJ, Valla M, Bofin AM
    Basal markers and prognosis in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4182.
    PubMed     Text format     Abstract available


  62. VADAPARAMPIL ST, Christie J, Donovan KA, Kim J, et al
    Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2017 Mar 3. doi: 10.1007/s10549-017-4173.
    PubMed     Text format     Abstract available


  63. RAUSCHER GH, Silva A, Pauls H, Frasor J, et al
    Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4166.
    PubMed     Text format     Abstract available


  64. SALGADO TM, Davis EJ, Farris KB, Fawaz S, et al
    Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Breast Cancer Res Treat. 2017 Mar 1. doi: 10.1007/s10549-017-4177.
    PubMed     Text format     Abstract available


    February 2017
  65. RAPHAEL J, Paramsothy T, Li N, Lee J, et al
    A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4167.
    PubMed     Text format     Abstract available


  66. MATSUDA N, Lim B, Wang Y, Krishnamurthy S, et al
    Identification of frequent somatic mutations in inflammatory breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4165.
    PubMed     Text format     Abstract available


  67. ORUCEVIC A, Bell JL, McNabb AP, Heidel RE, et al
    Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4170.
    PubMed     Text format     Abstract available


  68. ROBERTS MC, Miller DP, Shak S, Petkov VI, et al
    Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4162.
    PubMed     Text format     Abstract available


  69. PARK HS, Sohn J, Kim SI, Park S, et al
    Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 27. doi: 10.1007/s10549-017-4175.
    PubMed     Text format     Abstract available


  70. CHAKRABORTY A, Hatzis C, DiGiovanna MP
    Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
    Breast Cancer Res Treat. 2017 Feb 24. doi: 10.1007/s10549-017-4169.
    PubMed     Text format     Abstract available


  71. YEONG J, Thike AA, Lim JC, Lee B, et al
    Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4161.
    PubMed     Text format     Abstract available


  72. IGNATOV T, Eggemann H, Burger E, Costa SD, et al
    Management of small T1a/b breast cancer by tumor subtype.
    Breast Cancer Res Treat. 2017 Feb 23. doi: 10.1007/s10549-017-4168.
    PubMed     Text format     Abstract available


  73. ZETTERLUND LH, Frisell J, Zouzos A, Axelsson R, et al
    Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4164.
    PubMed     Text format     Abstract available


  74. LIEU TA, Ray GT, Prausnitz SR, Habel LA, et al
    Oncologist and organizational factors associated with variation in breast cancer multigene testing.
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4158.
    PubMed     Text format     Abstract available


  75. GASTELUM GM, Iqbal C, Hilsenbeck SG, Rimawi MF, et al
    Retrospective review of genomic testing in breast cancer: Does it improve outcome?
    Breast Cancer Res Treat. 2017 Feb 21. doi: 10.1007/s10549-017-4154.
    PubMed     Text format     Abstract available


  76. VAN NIJNATTEN TJ, Simons JM, Moossdorff M, de Munck L, et al
    Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4157.
    PubMed     Text format     Abstract available


  77. ZETTERLUND L, Celebioglu F, Axelsson R, de Boniface J, et al
    Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4163.
    PubMed     Text format     Abstract available


  78. PARISE CA, Caggiano V
    Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
    Breast Cancer Res Treat. 2017 Feb 17. doi: 10.1007/s10549-017-4159.
    PubMed     Text format     Abstract available


  79. PARK B, Sohn JY, Yoon KA, Lee KS, et al
    Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4142.
    PubMed     Text format     Abstract available


  80. GOORTS B, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4155.
    PubMed     Text format     Abstract available


  81. HSIEH YC, Tu SH, Su CT, Cho EC, et al
    A polygenic risk score for breast cancer risk in a Taiwanese population.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4144.
    PubMed     Text format     Abstract available


  82. INWALD EC, Ortmann O, Koller M, Zeman F, et al
    Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
    Breast Cancer Res Treat. 2017 Feb 15. doi: 10.1007/s10549-017-4151.
    PubMed     Text format     Abstract available


  83. LERNER-ELLIS J, Donenberg T, Ahmed H, George S, et al
    A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4148.
    PubMed     Text format     Abstract available


  84. HWANG KT, Kim YA, Kim J, Chu AJ, et al
    The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer.
    Breast Cancer Res Treat. 2017 Feb 13. doi: 10.1007/s10549-017-4153.
    PubMed     Text format     Abstract available


  85. THOMAS JS, Hanby AM, Russell N, van Tienhoven G, et al
    The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4145.
    PubMed     Text format     Abstract available


  86. MARINAC CR, Nelson SH, Flatt SW, Natarajan L, et al
    Sleep duration and breast cancer prognosis: perspectives from the Women's Healthy Eating and Living Study.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4140.
    PubMed     Text format     Abstract available


  87. LIM EA, Gunther JE, Kim HK, Flexman M, et al
    Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4150.
    PubMed     Text format     Abstract available


  88. YEO SK, French R, Spada F, Clarkson R, et al
    Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
    Breast Cancer Res Treat. 2017 Feb 11. doi: 10.1007/s10549-017-4149.
    PubMed     Text format     Abstract available


  89. SONG SE, Shin SU, Moon HG, Ryu HS, et al
    MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4143.
    PubMed     Text format     Abstract available


  90. SHAITELMAN SF, Chiang YJ, Griffin KD, De Snyder SM, et al
    Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4116.
    PubMed     Text format    


  91. PARIKH RP, Odom EB, Yu L, Colditz GA, et al
    Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 Feb 9. doi: 10.1007/s10549-017-4146.
    PubMed     Text format     Abstract available


  92. TAMAKI K, Fukuyama AK, Terukina S, Kamada Y, et al
    Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4134.
    PubMed     Text format     Abstract available


  93. RAYCHAUDHURI M, Bronger H, Buchner T, Kiechle M, et al
    MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4132.
    PubMed     Text format     Abstract available


  94. IWATA H, Masuda N, Yamamoto D, Sagara Y, et al
    Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4138.
    PubMed     Text format     Abstract available


  95. STEINDORF K, Wiskemann J, Ulrich CM, Schmidt ME, et al
    Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial.
    Breast Cancer Res Treat. 2017 Feb 8. doi: 10.1007/s10549-017-4141.
    PubMed     Text format     Abstract available


  96. MEHTA GA, Parker JS, Silva GO, Hoadley KA, et al
    Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4139.
    PubMed     Text format     Abstract available


  97. HIGGINS M, Curigliano G, Dieras V, Kuemmel S, et al
    Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4130.
    PubMed     Text format     Abstract available


  98. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Weltzien EK, et al
    Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2017 Feb 7. doi: 10.1007/s10549-017-4133.
    PubMed     Text format     Abstract available


  99. WITZEL I, Marx AK, Muller V, Wikman H, et al
    Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.
    Breast Cancer Res Treat. 2017 Feb 6. doi: 10.1007/s10549-017-4135.
    PubMed     Text format     Abstract available


  100. VALLE LF, Agarwal S, Bickel KE, Herchek HA, et al
    Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2017 Feb 3. doi: 10.1007/s10549-017-4118.
    PubMed     Text format     Abstract available


  101. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.
    Breast Cancer Res Treat. 2017 Feb 2. doi: 10.1007/s10549-017-4106.
    PubMed     Text format     Abstract available


  102. HAMILTON JG, Genoff MC, Salerno M, Amoroso K, et al
    Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4123.
    PubMed     Text format     Abstract available


  103. LEE JA, Yoo JE, Park HS
    Metabolic syndrome and incidence of breast cancer in middle-aged Korean women: a nationwide cohort study.
    Breast Cancer Res Treat. 2017 Feb 1. doi: 10.1007/s10549-017-4131.
    PubMed     Text format     Abstract available


    January 2017
  104. DETHLEFSEN C, Pedersen KS, Hojman P
    Every exercise bout matters: linking systemic exercise responses to breast cancer control.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4129.
    PubMed     Text format     Abstract available


  105. CARMICHAEL H, Matsen C, Freer P, Kohlmann W, et al
    Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4122.
    PubMed     Text format     Abstract available


  106. VAN UDEN DJ, Bretveld R, Siesling S, de Wilt JH, et al
    Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    Breast Cancer Res Treat. 2017 Jan 30. doi: 10.1007/s10549-017-4119.
    PubMed     Text format     Abstract available


  107. PEREZ M, Schootman M, Hall LE, Jeffe DB, et al
    Accelerated partial breast irradiation compared with whole breast radiation therapy: a breast cancer cohort study measuring change in radiation side-effects severity and quality of life.
    Breast Cancer Res Treat. 2017 Jan 28. doi: 10.1007/s10549-017-4121.
    PubMed     Text format     Abstract available


  108. VALLA M, Engstrom MJ, Ytterhus B, Hansen AK, et al
    FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
    Breast Cancer Res Treat. 2017 Jan 25. doi: 10.1007/s10549-017-4125.
    PubMed     Text format     Abstract available


  109. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
    Breast Cancer Res Treat. 2017 Jan 21. doi: 10.1007/s10549-017-4114.
    PubMed     Text format    


  110. MA D, Jiang YZ, Liu XY, Liu YR, et al
    Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4113.
    PubMed     Text format     Abstract available


  111. ALTUNDAG K
    Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4109.
    PubMed     Text format    


  112. RIZZOLO P, Silvestri V, Ottini L
    Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies.
    Breast Cancer Res Treat. 2017 Jan 16. doi: 10.1007/s10549-017-4108.
    PubMed     Text format    


  113. MATSUO S, Watanabe J, Mitsuya K, Hayashi N, et al
    Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
    Breast Cancer Res Treat. 2017 Jan 13. doi: 10.1007/s10549-017-4107.
    PubMed     Text format     Abstract available


  114. GULDBERG TL, Christensen S, Zachariae R, Jensen AB, et al
    Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity: data from a nationwide Danish cohort.
    Breast Cancer Res Treat. 2017 Jan 11. doi: 10.1007/s10549-016-4099.
    PubMed     Text format     Abstract available


  115. LEONE BA, Leone J, Leone JP
    Breast cancer is a systemic disease rather than an anatomical process.
    Breast Cancer Res Treat. 2017 Jan 9. doi: 10.1007/s10549-017-4104.
    PubMed     Text format    


  116. HEO J, Chun M, Oh YT, Noh OK, et al
    Psychiatric comorbidities among breast cancer survivors in South Korea: a nationwide population-based study.
    Breast Cancer Res Treat. 2017 Jan 7. doi: 10.1007/s10549-016-4097.
    PubMed     Text format     Abstract available


  117. RADMANESH H, Spethmann T, Enssen J, Schurmann P, et al
    Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-016-4100.
    PubMed     Text format     Abstract available


  118. ALTUNDAG K
    The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed!
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4103.
    PubMed     Text format    


  119. RAMANATHAN R, Olex AL, Dozmorov M, Bear HD, et al
    Angiopoietin pathway gene expression associated with poor breast cancer survival.
    Breast Cancer Res Treat. 2017 Jan 6. doi: 10.1007/s10549-017-4102.
    PubMed     Text format     Abstract available


  120. EGELAND EV, Boye K, Park D, Synnestvedt M, et al
    Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4096.
    PubMed     Text format     Abstract available


  121. TSANG JY, Au WL, Lo KY, Ni YB, et al
    PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Breast Cancer Res Treat. 2017 Jan 5. doi: 10.1007/s10549-016-4095.
    PubMed     Text format     Abstract available


  122. KAKUGAWA Y, Tada H, Kawai M, Suzuki T, et al
    Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples.
    Breast Cancer Res Treat. 2017 Jan 2. doi: 10.1007/s10549-016-4094.
    PubMed     Text format     Abstract available


    December 2016
  123. ECHAVARRIA I, Granja M, Bueno C, Lopez-Tarruella S, et al
    Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016 Dec 31. doi: 10.1007/s10549-016-4098.
    PubMed     Text format     Abstract available


  124. OTSUJI K, Sasaki T, Tanaka A, Kunita A, et al
    Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 30. doi: 10.1007/s10549-016-4092.
    PubMed     Text format     Abstract available


  125. SHAITELMAN SF
    Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4089.
    PubMed     Text format     Abstract available


  126. LI Y, Kurian AW, Bondarenko I, Taylor JM, et al
    The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 23. doi: 10.1007/s10549-016-4086.
    PubMed     Text format     Abstract available


  127. PRITZLAFF M, Summerour P, McFarland R, Li S, et al
    Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4085.
    PubMed     Text format     Abstract available


  128. YAMAMOTO D, Sato N, Rai Y, Yamamoto Y, et al
    Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4075.
    PubMed     Text format     Abstract available


  129. DE VRIES SCHULTINK AH, Alexi X, van Werkhoven E, Madlensky L, et al
    An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4083.
    PubMed     Text format     Abstract available


  130. SHIAO J, Thomas KM, Rahimi AS, Rao R, et al
    Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec 22. doi: 10.1007/s10549-016-4081.
    PubMed     Text format     Abstract available


  131. HAWLEY ST, Janz NK, Griffith KA, Jagsi R, et al
    Recurrence risk perception and quality of life following treatment of breast cancer.
    Breast Cancer Res Treat. 2016 Dec 21. doi: 10.1007/s10549-016-4082.
    PubMed     Text format     Abstract available


  132. BERTOLI G, Cava C, Diceglie C, Martelli C, et al
    MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4079.
    PubMed     Text format     Abstract available


  133. DEN BROK WD, Speers CH, Gondara L, Baxter E, et al
    Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    Breast Cancer Res Treat. 2016 Dec 20. doi: 10.1007/s10549-016-4080.
    PubMed     Text format     Abstract available


  134. LEONE BA, Vallejo CT, Romero AO, Machiavelli MR, et al
    Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  135. LI S, Liu J, Virnig BA, Collins AJ, et al
    Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  136. UHM KE, Yoo JS, Chung SH, Lee JD, et al
    Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  137. VAN GELDER M, Vanclee A, van Elssen CH, Hupperets P, et al
    Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  138. YAO S, Zhang Y, Tang L, Roh JM, et al
    Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  139. ADEMUYIWA FO, Tao Y, Luo J, Weilbaecher K, et al
    Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  140. HABRAKEN V, van Nijnatten TJ, de Munck L, Moossdorff M, et al
    Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  141. ZICK SM, Colacino J, Cornellier M, Khabir T, et al
    Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  142. TAVERA-TAPIA A, Perez-Cabornero L, Macias JA, Ceballos MI, et al
    Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  143. CHUNG YR, Kim HJ, Jang MH, Park SY, et al
    Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    November 2016
  144. SAITO R, Miki Y, Hata S, Ishida T, et al
    Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  145. LI X, Yang J, Peng L, Sahin AA, et al
    Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  146. SAGARA A, Igarashi K, Otsuka M, Kodama A, et al
    Endocan as a prognostic biomarker of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  147. WANG RX, Chen S, Jin X, Chen CM, et al
    Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  148. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  149. BOURKE MG, Salwa SP, Sadadcharam M, Whelan MC, et al
    Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: Ten-year audit of single centre experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  150. FREEDMAN RA, Seisler DK, Foster JC, Sloan JA, et al
    Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  151. ALTUNDAG K
    First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  152. HUANG J, Woods P, Normolle D, Goff JP, et al
    Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  153. SHI M, O'Brien KM, Sandler DP, Taylor JA, et al
    Previous GWAS hits in relation to young-onset breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  154. MCNAMARA KM, Oguro S, Omata F, Kikuchi K, et al
    The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  155. CONNOR AE, Visvanathan K, Baumgartner KB, Baumgartner RN, et al
    Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  156. MASALA G, Bendinelli B, Assedi M, Occhini D, et al
    Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  157. CALIP GS, Elmore JG, Boudreau DM
    Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  158. AMARA D, Wolf DM, van 't Veer L, Esserman L, et al
    Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  159. CHOWDHURY M, Euhus D, Onega T, Biswas S, et al
    A model for individualized risk prediction of contralateral breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  160. BRAUNSTEIN LZ, Taghian AG, Niemierko A, Salama L, et al
    Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  161. JANKOWSKI C, Guiu S, Cortet M, Charon-Barra C, et al
    Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  162. MERZENICH H, Bartkowiak D, Schmidberger H, Schmidt M, et al
    3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    October 2016
  163. HARBECK N, Saupe S, Jager E, Schmidt M, et al
    A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  164. MORAN O, Nikitina D, Royer R, Poll A, et al
    Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  165. HAMDI Y, Soucy P, Kuchenbaeker KB, Pastinen T, et al
    Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  166. IQBAL J, Ginsburg O, Giannakeas V, Rochon PA, et al
    The impact of nodal micrometastasis on mortality among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  167. JANSSEN N, Fortis SP, Speigl L, Haritos C, et al
    Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  168. GAUTAM J, Bae YK, Kim JA
    Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  169. CHLEBOWSKI RT, Pan K, Col NF
    Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  170. FERNANDES R, Mazzarello S, Stober C, Vandermeer L, et al
    Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  171. KIM H, Cho DY, Choi DH, Oh M, et al
    Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  172. KOTSOPOULOS J, Singer C, Narod SA
    Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  173. DUGUE PA, Milne RL, Southey MC
    A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  174. WANG C, Mu Z, Chervoneva I, Austin L, et al
    Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  175. CHENG F, Zhao J, Hanker AB, Brewer MR, et al
    Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  176. NEUHOUSER ML, Smith AW, George SM, Gibson JT, et al
    Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  177. SCHONBERG MA, Li VW, Eliassen AH, Davis RB, et al
    Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  178. PETRELLI F, Barni S, Bregni G, de Braud F, et al
    Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  179. CHURILLA TM, Egleston BL, Murphy CT, Sigurdson ER, et al
    Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  180. LEE JS, Magbanua MJ, Park JW
    Circulating tumor cells in breast cancer: applications in personalized medicine.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  181. BRZEZINSKA M, Williams LJ, Thomas J, Michael Dixon J, et al
    Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  182. DICKENS C, Pfeiffer RM, Anderson WF, Duarte R, et al
    Investigation of breast cancer sub-populations in black and white women in South Africa.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  183. CHEON H, Kim HJ, Lee SW, Kim DH, et al
    Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  184. CAZZANIGA ME, Cortesi L, Ferzi A, Scaltriti L, et al
    Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  185. HENNIGS A, Riedel F, Marme F, Sinn P, et al
    Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  186. LANCZKY A, Nagy A, Bottai G, Munkacsy G, et al
    miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  187. VAN MAAREN MC, de Munck L, Jobsen JJ, Poortmans P, et al
    Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  188. LI Z, Heng J, Yan J, Guo X, et al
    Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  189. NORDENSKJOLD A, Fohlin H, Fornander T, Lofdahl B, et al
    Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  190. REIX N, Malina C, Chenard MP, Bellocq JP, et al
    A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  191. HERVIK JB, Stub T
    Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  192. GOLSHAN M, Cirrincione CT, Sikov WM, Carey LA, et al
    Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  193. POLLOCK YG, Blackford AL, Jeter SC, Wright J, et al
    Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  194. ELSHOF LE, Schaapveld M, Schmidt MK, Rutgers EJ, et al
    Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
    Breast Cancer Res Treat. 2016;159:553-63.
    PubMed     Text format     Abstract available


  195. DEUTSCH TM, Riethdorf S, Nees J, Hartkopf AD, et al
    Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  196. ALIMUJIANG A, Mo M, Liu Y, Huang NS, et al
    The association between China's Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    September 2016
  197. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  198. ARISTEI C, Kaidar-Person O, Arenas M, Coles C, et al
    The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  199. HARTMAN EK, Eslick GD
    The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  200. TIAINEN S, Oikari S, Tammi M, Rilla K, et al
    High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  201. VAN DER POL CC, Lacle MM, Witkamp AJ, Kornegoor R, et al
    Prognostic models in male breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  202. BEABER EF, Tosteson AN, Haas JS, Onega T, et al
    Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  203. YANG EJ, Ahn S, Kim EK, Kang E, et al
    Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  204. KONO M, Fujii T, Lyons GR, Huo L, et al
    Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  205. ZHENG Q, Xia W, Lu Q, Hong R, et al
    Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  206. JOHNSTON S, Basik M, Hegg R, Lausoontornsiri W, et al
    Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  207. DIABY V, Adunlin G, Ali AA, Zeichner SB, et al
    Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  208. CEJALVO JM, Perez-Fidalgo JA, Ribas G, Burgues O, et al
    Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  209. ENG LG, Dawood S, Sopik V, Haaland B, et al
    Ten-year survival in women with primary stage IV breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  210. FREDHOLM H, Magnusson K, Lindstrom LS, Garmo H, et al
    Long-term outcome in young women with breast cancer: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  211. CATUCCI I, Casadei S, Ding YC, Volorio S, et al
    Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  212. TSUYUKI S, Senda N, Kanng Y, Yamaguchi A, et al
    Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  213. SISCO M, Kyrillos AM, Lapin BR, Wang CE, et al
    Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  214. O'SULLIVAN CC, Lindenberg M, Bryla C, Patronas N, et al
    ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  215. O'NEAL J, Clem A, Reynolds L, Dougherty S, et al
    Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  216. HAINSWORTH JD, Murphy PB, Alemar JR, Daniel BR, et al
    Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  217. RAPHAEL MJ, Biagi JJ, Kong W, Mates M, et al
    The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  218. WONG EM, Joo JE, McLean CA, Baglietto L, et al
    Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  219. DETHLEFSEN C, Lillelund C, Midtgaard J, Andersen C, et al
    Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  220. SAMUEL CA, Pinheiro LC, Reeder-Hayes KE, Walker JS, et al
    To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  221. HAMY AS, Bieche I, Lehmann-Che J, Scott V, et al
    BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  222. RYU JM, Lee HJ, Yoon TI, Lee ES, et al
    Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  223. PINHEIRO LC, Samuel CA, Reeder-Hayes KE, Wheeler SB, et al
    Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    August 2016
  224. COHN BA, Terry MB, Plumb M, Cirillo PM, et al
    Erratum to: Exposure to polychlorinated biphenyl (PCB) congeners measured shortly after giving birth and subsequent risk of maternal breast cancer before age 50.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  225. YOUNIS T, Rayson D, Jovanovic S, Skedgel C, et al
    Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  226. NERICH V, Saing S, Gamper EM, Kemmler G, et al
    Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  227. FENG J, Xu G, Liu J, Zhang N, et al
    Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  228. LE QA, Bae YH, Kang JH
    Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  229. XU M, Xu Y, Chen M, Li Y, et al
    Association study confirms two susceptibility loci for breast cancer in Chinese Han women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  230. NUNES RA, Wray L, Mete M, Herbolsheimer P, et al
    Genomic profiling of breast cancer in African-American women using MammaPrint.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  231. SHIEH Y, Hu D, Ma L, Huntsman S, et al
    Breast cancer risk prediction using a clinical risk model and polygenic risk score.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  232. LI T, Mello-Thoms C, Brennan PC
    Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  233. LI N, Thompson ER, Rowley SM, McInerny S, et al
    Reevaluation of RINT1 as a breast cancer predisposition gene.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  234. LEE DH, Park S, Lim SM, Lee MK, et al
    Resting heart rate as a prognostic factor for mortality in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available



  235. UK Breast Cancer Research Symposium 2016: Submitted Abstracts.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  236. ROGERS LQ, Courneya KS, Carter SJ, Anton PM, et al
    Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  237. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  238. HARANO K, Lei X, Gonzalez-Angulo AM, Murthy RK, et al
    Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  239. VERSCHOOR AM, Kuijer A, Verloop J, Van Gils CH, et al
    Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  240. GONG Z, Hong CC, Bandera EV, Adams-Campbell LL, et al
    Vigorous physical activity and risk of breast cancer in the African American breast cancer epidemiology and risk consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  241. ALESKANDARANY MA, Abduljabbar R, Ashankyty I, Elmouna A, et al
    Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  242. FARVID MS, Cho E, Eliassen AH, Chen WY, et al
    Lifetime grain consumption and breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  243. BAO T, Basal C, Seluzicki C, Li SQ, et al
    Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  244. PARSONS BM, Landercasper J, Smith AL, Go RS, et al
    21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  245. LI F, Armato SG, Giger ML, MacMahon H, et al
    Clinical significance of noncalcified lung nodules in patients with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  246. VALACHIS A, Garmo H, Weinman J, Fredriksson I, et al
    Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  247. FIGUEROA JD, Pfeiffer RM, Brinton LA, Palakal MM, et al
    Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  248. JOHANSSON H, Gandini S, Serrano D, Gjerde J, et al
    A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  249. NARAYAN AK, Visvanathan K, Harvey SC
    Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2016;158:583-9.
    PubMed     Text format     Abstract available


  250. SLIJKHUIS WA, Noorda EM, van der Zaag-Loonen H, Eenennaam MJ, et al
    Ultrasound-guided breast-conserving surgery for early-stage palpable and nonpalpable invasive breast cancer: decreased excision volume at unchanged tumor-free resection margin.
    Breast Cancer Res Treat. 2016;158:535-41.
    PubMed     Text format     Abstract available


  251. BEEK MA, Gobardhan PD, Schoenmaeckers EJ, Klompenhouwer EG, et al
    Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status.
    Breast Cancer Res Treat. 2016;158:421-32.
    PubMed     Text format     Abstract available


  252. HALPERN MT, Schrag D
    Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries.
    Breast Cancer Res Treat. 2016;158:573-81.
    PubMed     Text format     Abstract available


    July 2016
  253. TABUNG FK, Steck SE, Liese AD, Zhang J, et al
    Patterns of change over time and history of the inflammatory potential of diet and risk of breast cancer among postmenopausal women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  254. SCHOTT AF, Barlow WE, Van Poznak CH, Hayes DF, et al
    Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  255. DONENBERG T, Ahmed H, Royer R, Zhang S, et al
    A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  256. LEOPOLD C
    Author's response to "letter to the editor: lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer".
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  257. ALSHAREEDA AT, Negm OH, Aleskandarany MA, Green AR, et al
    Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  258. KEHL KL, Shen C, Litton JK, Arun B, et al
    Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  259. GENNARI A, Amadori D, Scarpi E, Farolfi A, et al
    Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  260. ROGAN S, Taeymans J, Luginbuehl H, Aebi M, et al
    Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  261. QIAN XL, Wen HY, Yang YL, Gu F, et al
    Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  262. GRANT WB
    Lower vitamin D status may explain racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  263. GREEN AR, Soria D, Powe DG, Nolan CC, et al
    Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  264. KWAN ML, Yao S, Lee VS, Roh JM, et al
    Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  265. WARNER ET, Ballman KV, Strand C, Boughey JC, et al
    Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  266. MURANEN TA, Mavaddat N, Khan S, Fagerholm R, et al
    Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  267. LEE PE, Tierney MC, Wu W, Pritchard KI, et al
    Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  268. BATTAGLIA TA, Darnell JS, Ko N, Snyder F, et al
    The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  269. LO-FO-WONG DN, de Haes HC, Aaronson NK, van Abbema DL, et al
    Predictors of enduring clinical distress in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  270. AHMAD A, Wang Z, Kong D, Ali S, et al
    Retraction Note to: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  271. AHMAD A, Wang Z, Kong D, Ali R, et al
    Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  272. BRENTNALL AR, Cuzick J, Byers H, Segal C, et al
    Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  273. YE ZJ, Liang MZ, Qiu HZ, Liu ML, et al
    Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  274. ADAMS SC, Segal RJ, McKenzie DC, Vallerand JR, et al
    Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  275. SECRETO G, Sieri S, Agnoli C, Grioni S, et al
    A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  276. NAHLEH ZA, Barlow WE, Hayes DF, Schott AF, et al
    SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  277. ZHANG J, Sun J, Chen J, Yao L, et al
    Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  278. GARONA J, Alonso DF
    Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  279. GIULIANI O, Mancini S, Puliti D, Caranci N, et al
    Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  280. SOPIK V, Iqbal J, Sun P, Narod SA, et al
    Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  281. ALESKANDARANY MA, Green AR, Ashankyty I, Elmouna A, et al
    Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  282. YANG M, Teng W, Qu Y, Wang H, et al
    Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  283. VEERARAGHAVAN J, Ma J, Hu Y, Wang XS, et al
    Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  284. PRUNERI G, Gray KP, Vingiani A, Viale G, et al
    Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  285. KOTOULA V, Karavasilis V, Zagouri F, Kouvatseas G, et al
    Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    June 2016
  286. VAN RAMSHORST MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, et al
    The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  287. LAN ZJ, Hu Y, Zhang S, Li X, et al
    GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor alpha activity in breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  288. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  289. BRIGHT EE, Petrie KJ, Partridge AH, Stanton AL, et al
    Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  290. NYROP KA, Williams GR, Muss HB, Shachar SS, et al
    Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  291. FREEDMAN RA, Viswanath K, Vaz-Luis I, Keating NL, et al
    Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  292. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  293. TIWARI SR, Mishra P, Raska P, Calhoun B, et al
    Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  294. DOEBAR SC, van den Broek EC, Koppert LB, Jager A, et al
    Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  295. KUROZUMI S, Padilla M, Kurosumi M, Matsumoto H, et al
    HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  296. ZEITZER JM, Nouriani B, Rissling MB, Sledge GW, et al
    Aberrant nocturnal cortisol and disease progression in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  297. COLACINO JA, McDermott SP, Sartor MA, Wicha MS, et al
    Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  298. DILLEKAS H, Demicheli R, Ardoino I, Jensen SA, et al
    The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  299. SMYTH LM, Iyengar NM, Chen MF, Popper SM, et al
    Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  300. HICKEY M, Marino JL, Braat S, Wong S, et al
    A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  301. KEINAN-BOKER L, Levine H, Derazne E, Molina-Hazan V, et al
    Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  302. HIRKO KA, Fortner RT, Hankinson SE, Wu T, et al
    Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  303. ARUN BK, Gong Y, Liu D, Litton JK, et al
    Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  304. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  305. NEUGUT AI, Hillyer GC, Kushi LH, Lamerato L, et al
    A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  306. HEIN A, Gass P, Walter CB, Taran FA, et al
    Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  307. MATTER-WALSTRA K, Ruhstaller T, Klingbiel D, Schwenkglenks M, et al
    Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  308. GONG IY, Verma S, Yan AT, Ko DT, et al
    Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  309. MUNIZ J, Kidwell KM, Henry NL
    Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  310. DI MEGLIO A, Freedman RA, Lin NU, Barry WT, et al
    Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  311. ROBLES AJ, Cai S, Cichewicz RH, Mooberry SL, et al
    Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  312. YAO H, Veine DM, Livant DL
    Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting alpha5beta1 integrin.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  313. AKINYEMIJU T, Moore JX, Ojesina AI, Waterbor JW, et al
    Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  314. ZHOU Y, Ouyang T, Xie Y, Wang T, et al
    A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  315. SZALAYOVA G, Ogrodnik A, Spencer B, Wade J, et al
    Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    May 2016
  316. CHEN Y, Jiang L, Gao B, Cheng ZY, et al
    Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  317. KWON JS, Pansegrau G, Nourmoussavi M, Hammond G, et al
    Long-term consequences of ovarian ablation for premenopausal breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  318. LIU YL, Saraf A, Lee SM, Zhong X, et al
    Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  319. LEWIN R, Sulkes A, Shochat T, Tsoref D, et al
    Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  320. WIRTZ RM, Sihto H, Isola J, Heikkila P, et al
    Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  321. CHEN L, Cook LS, Tang MC, Porter PL, et al
    Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  322. ORUCEVIC A, Heidel RE, Bell JL
    Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  323. BOQUIREN VM, Hack TF, Thomas RL, Towers A, et al
    A longitudinal analysis of chronic arm morbidity following breast cancer surgery.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  324. VILLARREAL-GARZA C, Bargallo-Rocha JE, Soto-Perez-de-Celis E, Lasa-Gonsebatt F, et al
    Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  325. ZHOU W, Zhao Y, Pan H, Li Q, et al
    Great tumour burden in the axilla may influence lymphatic drainage in breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  326. SINGH K, Tantravahi U, Lomme MM, Pasquariello T, et al
    Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HE
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  327. SULAICA E, Han T, Wang W, Bhat R, et al
    Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  328. CHEN X, Hu H, He L, Yu X, et al
    A novel subtype classification and risk of breast cancer by histone modification profiling.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  329. HUO J, Smith BD, Giordano SH, Reece GP, et al
    Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  330. JACOT W, Pons E, Frenel JS, Guiu S, et al
    Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  331. SCHMIDT N, Jacob L, Coleman R, Kostev K, et al
    Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  332. WISE R, Duhachek-Muggy S, Qi Y, Zolkiewski M, et al
    Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  333. BUSTREO S, Osella-Abate S, Cassoni P, Donadio M, et al
    Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  334. SUN F, Skolny MN, Swaroop MN, Rawal B, et al
    The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  335. ROSENSTOCK AS, Lei X, Tripathy D, Hortobagyi GN, et al
    Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  336. PENG C, Chen H, Wallwiener M, Modugno C, et al
    Plasma S100P level as a novel prognostic marker of metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  337. SPEYER CL, Nassar MA, Hachem AH, Bukhsh MA, et al
    Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    April 2016
  338. INOUE K, Saito T, Okubo K, Kimizuka K, et al
    Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  339. KWONG A, Shin VY, Cheuk IW, Chen J, et al
    Germline RECQL mutations in high risk Chinese breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  340. FELDER TM, Do DP, Lu ZK, Lal LS, et al
    Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  341. THAKKAR A, Wang B, Picon-Ruiz M, Buchwald P, et al
    Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  342. AGRESTI R, Meneghini E, Baili P, Minicozzi P, et al
    Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  343. KARAKATSANIS A, Christiansen PM, Fischer L, Hedin C, et al
    The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  344. CONNOR AE, Visvanathan K, Baumgartner KB, Baumgartner RN, et al
    Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  345. GREEN AR, Soria D, Powe DG, Nolan CC, et al
    Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  346. RAYSON D, Lupichuk S, Potvin K, Dent S, et al
    Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  347. PALUCH-SHIMON S, Friedman E, Berger R, Papa M, et al
    Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  348. TABUCHI Y, Shimoda M, Kagara N, Naoi Y, et al
    Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  349. BERGEN ES, Tichy C, Berghoff AS, Rudas M, et al
    Prognostic impact of breast cancer subtypes in elderly patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  350. GALLAGHER CM, More K, Kamath T, Masaquel A, et al
    Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  351. LAVAUD P, Rousseau B, Ajgal Z, Arrondeau J, et al
    Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  352. KIM SH, Hahm ER, Arlotti JA, Samanta SK, et al
    Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  353. MARTEL F, Guedes M, Keating E
    Effect of polyphenols on glucose and lactate transport by breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  354. KIM JY, Suh HB, Kang HJ, Shin JK, et al
    Apparent diffusion coefficient of breast cancer and normal fibroglandular tissue in diffusion-weighted imaging: the effects of menstrual cycle and menopausal status.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  355. HERSHMAN DL, Kushi LH, Hillyer GC, Coromilas E, et al
    Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  356. CAPPER CP, Larios JM, Sikora MJ, Johnson MD, et al
    The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  357. CABARROU B, Belin L, Somda SM, Falcou MC, et al
    Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  358. PAN K, Chlebowski RT, Simon MS, Ray RM, et al
    Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  359. KIM YA, Lee HJ, Heo SH, Park HS, et al
    MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  360. UENO NT, Mamounas EP
    Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  361. DROOGER JC, Heemskerk-Gerritsen BA, Smallenbroek N, Epskamp C, et al
    Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  362. MURTAGH G, Lyons T, O'Connell E, Ballot J, et al
    Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  363. DU J, Li L, Ou Z, Kong C, et al
    Erratum to: FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  364. IWAMOTO T, Kumamaru H, Miyata H, Tomotaki A, et al
    Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  365. LEONE JP, Zwenger AO, Iturbe J, Leone J, et al
    Prognostic factors in male breast cancer: a population-based study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  366. LIEDE A, Jerzak KJ, Hernandez RK, Wade SW, et al
    The incidence of bone metastasis after early-stage breast cancer in Canada.
    Breast Cancer Res Treat. 2016;156:587-95.
    PubMed     Text format     Abstract available


  367. BLYTH K, Carter P, Morrissey B, Chelala C, et al
    SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs.
    Breast Cancer Res Treat. 2016;156:447-52.
    PubMed     Text format     Abstract available


  368. GONZALEZ-RIVERA M, Lobo M, Lopez-Tarruella S, Jerez Y, et al
    Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    Breast Cancer Res Treat. 2016;156:507-15.
    PubMed     Text format     Abstract available


  369. VAN ROOZENDAAL LM, Goorts B, Klinkert M, Keymeulen KB, et al
    Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
    Breast Cancer Res Treat. 2016;156:517-25.
    PubMed     Text format     Abstract available


  370. AUMANN K, Niermann K, Asberger J, Wellner U, et al
    Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens.
    Breast Cancer Res Treat. 2016;156:495-500.
    PubMed     Text format     Abstract available


  371. EVANS CN, Brewer NT, Vadaparampil ST, Boisvert M, et al
    Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
    Breast Cancer Res Treat. 2016;156:549-55.
    PubMed     Text format     Abstract available


  372. LIM ST, Choi JE, Kim SJ, Kim HA, et al
    Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population.
    Breast Cancer Res Treat. 2016;156:473-83.
    PubMed     Text format     Abstract available


    March 2016
  373. YAO L, Sun J, Zhang J, He Y, et al
    Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  374. GHOLAMI S, Marano A, Chen NG, Aguilar RJ, et al
    Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  375. GREENLEE H, Sardo Molmenti CL, Falci L, Ulmer R, et al
    High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  376. JOHNS C, Seav SM, Dominick SA, Gorman JR, et al
    Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  377. VAN ROOZENDAAL LM, Smit LH, Duijsens GH, de Vries B, et al
    Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  378. GREENLEE H, Crew KD, Capodice J, Awad D, et al
    Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  379. LOVE RR, Love SM
    Peri-operative biology in primary breast cancer: a credible therapeutic target.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  380. CHAPMAN JW, Shepherd LE, Ingle JN, Muss HB, et al
    Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  381. KWAN ML, Shi JM, Habel LA, Song J, et al
    Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  382. HENIN E, Meille C, Barbolosi D, You B, et al
    Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  383. YIN C, Li H, Zhang B, Liu Y, et al
    Erratum to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  384. KRAMER GM, Leenders MW, Schijf LJ, Go HL, et al
    Is ultrasound-guided fine-needle aspiration cytology of adequate value in detecting breast cancer patients with three or more positive axillary lymph nodes?
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  385. LIMENTANI SA, Campone M, Dorval T, Curigliano G, et al
    A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  386. NISHIJIMA TF, Suzuki M, Muss HB
    A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  387. HUZARSKI T, Byrski T, Gronwald J, Cybulski C, et al
    The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  388. CURIGLIANO G, Romieu G, Campone M, Dorval T, et al
    A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  389. KIDA K, Ishikawa T, Yamada A, Shimada K, et al
    Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  390. RANGEL MC, Bertolette D, Castro NP, Klauzinska M, et al
    Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  391. ENGELS CC, Kiderlen M, Bastiaannet E, van Eijk R, et al
    The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  392. CHECK DK, Reeder-Hayes KE, Basch EM, Zullig LL, et al
    Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  393. VETTER L, Keller M, Bruckner T, Golatta M, et al
    Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  394. MATSUMOTO H, Thike AA, Li H, Yeong J, et al
    Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  395. TANG J, Deng R, Luo RZ, Shen GP, et al
    Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  396. PANDIRI I, Chen Y, Joe Y, Kim HJ, et al
    Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  397. NUNEZ O, Roman A, Johnson SR, Inoue Y, et al
    Study of breast cancer incidence in patients of lymphangioleiomyomatosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  398. MCCULLOUGH LE, Chen J, Cho YH, Khankari NK, et al
    DNA methylation modifies the association between obesity and survival after breast cancer diagnosis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  399. SHEN H, Yang Y, Zhao L, Yuan J, et al
    Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  400. JAIN MM, Gupte SU, Patil SG, Pathak AB, et al
    Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  401. ZHU T, Liu CL, Zhang YF, Liu YH, et al
    A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  402. CONANT EF, Beaber EF, Sprague BL, Herschorn SD, et al
    Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


    February 2016
  403. WELT A, Marschner N, Lerchenmueller C, Decker T, et al
    Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  404. TURTURRO SB, Najor MS, Ruby CE, Cobleigh MA, et al
    Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  405. AKECHI T, Momino K, Iwata H
    Author reply: Brief screening of breast cancer survivors with distressing fear of recurrence.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  406. THEWES B, van de Wal M, Prins J
    Comments on 'Brief screening of patients with distressing fear of recurrence in breast cancer survivors' by Akechi et al., Breast Cancer Res Treat, 2015, 153(2): pp. 475-476.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  407. HARTKOPF AD, Wallwiener M, Kommoss S, Taran FA, et al
    Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  408. COLLINS IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, et al
    iPrevent: a tailored, web-based, decision support tool for breast cancer risk assessment and management.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  409. MARTIN M, Brase JC, Ruiz A, Prat A, et al
    Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  410. DIECI MV, Smutna V, Scott V, Yin G, et al
    Whole exome sequencing of rare aggressive breast cancer histologies.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  411. HOPPER JL, Nguyen TL, Stone J, Aujard K, et al
    Childhood body mass index and adult mammographic density measures that predict breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  412. LI L, Gao P, Li Y, Shen Y, et al
    Erratum to: JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  413. ALESKANDARANY MA, Agarwal D, Negm OH, Ball G, et al
    The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  414. LIU J, Guo H, Mao K, Zhang K, et al
    Impact of estrogen receptor-beta expression on breast cancer prognosis: a meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  415. OCANA A, Perez-Pena J, Diez-Gonzalez L, Sanchez-Corrales V, et al
    Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  416. DIONYSSIOU D, Demiri E, Tsimponis A, Sarafis A, et al
    A randomized control study of treating secondary stage II breast cancer-related lymphoedema with free lymph node transfer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  417. BISWAS S, Sengupta S, Roy Chowdhury S, Jana S, et al
    Erratum to: CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  418. PESSETTO ZY, Yan Y, Bessho T, Natarajan A, et al
    Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  419. HUNG SW, Chiu CF, Chen TA, Chu CL, et al
    Erratum to: Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  420. MURTHY P, Kidwell KM, Schott AF, Merajver SD, et al
    Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  421. HUANG X, He D, Ming J, He Y, et al
    High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  422. HIRKO KA, Willett WC, Hankinson SE, Rosner BA, et al
    Healthy dietary patterns and risk of breast cancer by molecular subtype.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  423. VAZ-LUIS I, Hughes ME, Cronin A, Rugo HS, et al
    Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  424. NELSON SH, Marinac CR, Patterson RE, Nechuta SJ, et al
    Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  425. DUGGAN C, Stanczyk F, Campbell K, Neuhouser ML, et al
    Associations of sex steroid hormones with mortality in women with breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  426. CAMPBELL MR, Zhang H, Ziaee S, Ruiz-Saenz A, et al
    Effective treatment of HER2-amplified breast cancer by targeting HER3 and beta1 integrin.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  427. WANG Y, Wang Y, Li L
    Note of clarification regarding data about the association between the interleukin-1beta -31T>C polymorphism and breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format    


  428. RADISKY DC, Visscher DW, Frank RD, Vierkant RA, et al
    Natural history of age-related lobular involution and impact on breast cancer risk.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  429. LIAN ZQ, Wang Q, Zhang AQ, Zhang JY, et al
    Erratum to: A nomogram based on mammary ductoscopic indicators for evaluating the risk of breast cancer in intraductal neoplasms with nipple discharge.
    Breast Cancer Res Treat. 2016;155:619.
    PubMed     Text format    


  430. WANG Y, Chu X, Wang H
    Note of clarification regarding data on the association between the interleukin-1beta -511C>T polymorphism and breast cancer risk.
    Breast Cancer Res Treat. 2016;155:419-21.
    PubMed     Text format    


  431. FAN YS, Casas CE, Peng J, Watkins M, et al
    HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Breast Cancer Res Treat. 2016;155:457-62.
    PubMed     Text format     Abstract available


  432. EVANS DG, Lalloo F, Howell S, Verhoef S, et al
    Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
    Breast Cancer Res Treat. 2016;155:597-601.
    PubMed     Text format     Abstract available


  433. CHIEN AJ, Cockerill A, Fancourt C, Schmidt E, et al
    A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Breast Cancer Res Treat. 2016;155:521-30.
    PubMed     Text format     Abstract available


  434. MILLER CL, Coopey SB, Rafferty E, Gadd M, et al
    Comparison of intra-operative specimen mammography to standard specimen mammography for excision of non-palpable breast lesions: a randomized trial.
    Breast Cancer Res Treat. 2016;155:513-9.
    PubMed     Text format     Abstract available


  435. SHAPIRO AC, Adlis SA, Robien K, Kirstein MN, et al
    Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Breast Cancer Res Treat. 2016;155:501-12.
    PubMed     Text format     Abstract available


  436. JONGEN L, Paridaens R, Floris G, Wildiers H, et al
    Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Breast Cancer Res Treat. 2016;155:603-7.
    PubMed     Text format     Abstract available


  437. KNOBF MT, Jeon S, Smith B, Harris L, et al
    Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2016;155:491-500.
    PubMed     Text format     Abstract available


  438. SHEFFIELD BS, Kos Z, Asleh-Aburaya K, Wang XQ, et al
    Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Breast Cancer Res Treat. 2016;155:483-90.
    PubMed     Text format     Abstract available


  439. HASSETT MJ, Jiang W, Habel LA, Nekhlyudov L, et al
    Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
    Breast Cancer Res Treat. 2016;155:541-9.
    PubMed     Text format     Abstract available


    January 2016
  440. HAGSTROM AD, Marshall PW, Lonsdale C, Papalia S, et al
    The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  441. VIALE G, Slaets L, de Snoo FA, Bogaerts J, et al
    Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  442. GAUDET MM, Barrdahl M, Lindstrom S, Travis RC, et al
    Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  443. BROTHERS JM, Kidwell KM, Brown RK, Henry NL, et al
    Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  444. SORACE AG, Quarles CC, Whisenant JG, Hanker AB, et al
    Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  445. GREGORY WM, Twelves CJ, Bell R, Smye SW, et al
    Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  446. TUOMELA JM, Sandholm JA, Kaakinen M, Hayden KL, et al
    Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  447. KOTSOPOULOS J, Huzarski T, Gronwald J, Moller P, et al
    Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  448. DINE JL, O'Sullivan CC, Voeller D, Greer YE, et al
    The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  449. BLUM JL, Goncalves A, Efrat N, Debled M, et al
    A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  450. BARAC A, Lynce F, Smith KL, Mete M, et al
    Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  451. RUIZ-NARVAEZ EA, Haddad SA, Lunetta KL, Yao S, et al
    Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  452. FRYDENBERG H, Thune I, Lofterod T, Mortensen ES, et al
    Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  453. LIU CC, Teh R, Mozar CA, Baxter RC, et al
    Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and gamma-radiation on Na/K-ATPase and cell survival.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  454. NG T, Mazzarello S, Wang Z, Hutton B, et al
    Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  455. CUI F, Wu D, Wang W, He X, et al
    Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis.
    Breast Cancer Res Treat. 2016.
    PubMed     Text format     Abstract available


  456. BERTRAND KA, Burian RA, Eliassen AH, Willett WC, et al
    Adolescent intake of animal fat and red meat in relation to premenopausal mammographic density.
    Breast Cancer Res Treat. 2016;155:385-93.
    PubMed     Text format     Abstract available


  457. BISWAS S, Atienza P, Chipman J, Blackford AL, et al
    A two-stage approach to genetic risk assessment in primary care.
    Breast Cancer Res Treat. 2016;155:375-83.
    PubMed     Text format     Abstract available


  458. QUILES F, Menendez M, Tornero E, del Valle J, et al
    Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
    Breast Cancer Res Treat. 2016;155:253-60.
    PubMed     Text format     Abstract available


    December 2015
  459. SOPIK V, Nofech-Mozes S, Sun P, Narod SA, et al
    The relationship between local recurrence and death in early-stage breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  460. KEHL KL, Shen C, Litton JK, Arun B, et al
    Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  461. ACHKAR T, Wilson J, Simon J, Rosenzweig M, et al
    Metastatic breast cancer patients: attitudes toward tissue donation for rapid autopsy.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  462. NGEOW J, Sesock K, Eng C
    Breast cancer risk and clinical implications for germline PTEN mutation carriers.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  463. SAMSON M, Porter N, Orekoya O, Hebert JR, et al
    Progestin and breast cancer risk: a systematic review.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  464. SCHIMDT N, Jacob L, Coleman R, Kostev K, et al
    The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  465. FREEDMAN RA, Fedewa SA, Punglia RS, Lin CC, et al
    Factors associated with radiation therapy incompletion for patients with early-stage breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  466. VEQUAUD E, Desplanques G, Jezequel P, Juin P, et al
    Survivin contributes to DNA repair by homologous recombination in breast cancer cells.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  467. LIANG DH, Ensor JE, Liu ZB, Patel A, et al
    Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  468. DEL MASTRO L, Levaggi A, Michelotti A, Cavazzini G, et al
    5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  469. HANAI A, Ishiguro H, Sozu T, Tsuda M, et al
    Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  470. SCHROTH W, Winter S, Buttner F, Goletz S, et al
    Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  471. NEGM OH, Muftah AA, Aleskandarany MA, Hamed MR, et al
    Clinical utility of reverse phase protein array for molecular classification of breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  472. KOLBEN T, Augustin D, Armbrust R, Kolben TM, et al
    Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  473. JACOBS C, Kuchuk I, Bouganim N, Smith S, et al
    A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


    November 2015
  474. BRANHAM MT, Campoy E, Laurito S, Branham R, et al
    Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  475. CHLEBOWSKI RT, Haque R, Hedlin H, Col N, et al
    Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  476. ADUNLIN G, Cyrus JW, Dranitsaris G
    Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  477. WOLFE AR, Debeb BG, Lacerda L, Larson R, et al
    Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  478. LEYLAND-JONES B, Gray KP, Abramovitz M, Bouzyk M, et al
    ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  479. JAKES AD, Twelves C
    Breast cancer-related lymphoedema and venepuncture: a review and evidence-based recommendations.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  480. ALLMAN R, Dite GS, Hopper JL, Gordon O, et al
    SNPs and breast cancer risk prediction for African American and Hispanic women.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  481. BRAUNSTEIN LZ, Galland-Girodet S, Goldberg S, Warren LE, et al
    Long-term outcomes among breast cancer patients with extensive regional lymph node involvement: implications for locoregional management.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  482. THOMSEN KG, Lyng MB, Elias D, Vever H, et al
    Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  483. MU Z, Wang C, Ye Z, Austin L, et al
    Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  484. IMAMURA M, Nishimukai A, Higuchi T, Ozawa H, et al
    High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  485. SANFT T, Aktas B, Schroeder B, Bossuyt V, et al
    Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  486. CORTES J, Hudgens S, Twelves C, Perez EA, et al
    Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  487. SHEN Y, Wang Z, Loo LW, Ni Y, et al
    LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  488. DAMIOLA F, Schultz I, Barjhoux L, Sornin V, et al
    Mutation analysis of PALB2 gene in French breast cancer families.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  489. BRADLEY CJ, Dahman B, Jagsi R, Katz S, et al
    Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  490. MACACU A, Autier P, Boniol M, Boyle P, et al
    Active and passive smoking and risk of breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  491. LLOMBART-CUSSAC A, Bermejo B, Villanueva C, Delaloge S, et al
    SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  492. KYRO C, Zamora-Ros R, Scalbert A, Tjonneland A, et al
    Pre-diagnostic polyphenol intake and breast cancer survival: the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


    October 2015
  493. LEE JS, Melisko ME, Magbanua MJ, Kablanian AT, et al
    Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  494. DEMARK-WAHNEFRIED W, Colditz GA, Rock CL, Sedjo RL, et al
    Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  495. STAGL JM, Lechner SC, Carver CS, Bouchard LC, et al
    A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  496. CHIARELLI AM, Prummel MV, Muradali D, Shumak RS, et al
    Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


  497. GOBEL A, Browne AJ, Thiele S, Rauner M, et al
    Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Breast Cancer Res Treat. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: